

## PLATINUM INT'L HEALTH CARE FUND ARSN 107 023 530

29 February 2012

FACTS				FEES			
		¢24.70				N 11	
Portfolio Value		\$24.76 mn	0.02	Entry fee Exit fee		Nil Nil	
Fund commenced Minimum investment		10 November 2003 A\$20,000 or NZ\$25,000		Management Expense	Ratio/	1.54% per annum	
		A\$200 or NZ\$250 per mth/qtr		Indirect Cost Ratio (MI		(inclusive of investr	ment &
Income distribution date Annual, 30 June				,	administration cost		
Unit valuation		Sydney Business	Day	Brokerage paid		Nil	
Unit prices		Арр 1.0549	Red 1.0496	Buy/sell spread		0.5% total	
PERFORMANCE <sup>1</sup>			PERFORMANCE GRAPH_2				
		FUND %	<u>MSCI %</u>	\$30,000 ¬			
1 month		(0.12)	0.38	\$30,000			
3 months		2.01	2.53		Platinum	Int'l Health Care Fur	nd
6 months		3.29	6.07	\$27,000 -		27.2	
		5.26	3.47		<u> </u>		
1 year				\$24,000 -			
2 years (compound pa)		5.67	(1.24)			<u> </u>	<b>1</b>
3 years (compound pa)		8.46	(0.99)	¢21.000			<b></b>
5 years (compound pa)		0.93	(3.69)	\$21,000		T VVV V	<b>√</b> ₩
7 years (compound pa)		3.84	0.25		V.	MSCI AC World Heal	th Caro
Since inception (compoun	ıd pa)	2.93	0.86	\$18,000 -	V <sup>r</sup>	Heat	7.4%
<b>INVESTED POSITION</b> <sup>3</sup>							
<u> </u>	<u>ONG %</u>	<u>NET %</u>	CURRENCY %	\$15,000	1	1 1	
Belgium	3.5	3.5		2003	2005 2	2007 2009	2011
Brazil	1.4	1.4	1.4	Source: Factset and	l Platinum		
Canada	1.0	1.0	9.7		. 4		
China (Listed ex PRC)	1.2	1.2		TOP TEN POSITIONS			
Denmark	0.7	0.7		<u>STOCK</u>	<u>COUNTRY</u>	<u>INDUSTRY</u>	<u>%</u>
France	6.4	6.4		Sanofi SA	France	Pharmaceuticals	3.8
Germany	7.0	7.0		Teva Pharmaceuticals	United States	Pharmaceuticals	3.7
Italy	1.5	1.5		Gilead Sciences Inc	United States	Biotechnology	3.4
Japan	3.0	3.0	4.0	Roche Holding AG	Switzerland	Pharmaceuticals	3.3
Sweden	4.7	4.7	4.8	Qiagen NV	Germany	Health Equip & Ser	vices 3.3
Switzerland	7.1	7.1	1.8	Sartorius AG	Germany	Health Equip & Ser	vices 3.1
UK	2.2	2.2	2.3	Merck & Co Inc		Pharmaceuticals	3.0
US	33.7	30.6	29.8	Johnson & Johnson		Health Equip & Ser	
A Ċ	73.4	70.3	10 5	Medivir AB	Sweden	Pharmaceuticals	2.6
A\$ Euro			10.5	lpsen SA	France	Pharmaceuticals	2.6
Hong Kong			18.8 1.4				
Korea			3.4	INDUSTRY BREAKDO	WN <sup>3</sup>		
Norway			3.7				
Singapore			8.4	<u>SECTOR</u>			NET <u>%</u>
Cash & Accruals	26.6	29.7		Pharmaceuticals		37.1	37.1
Total	100.0	100.0	100.0	Health Equipment & S Biotechnology	ervices	15.1	13.7 14 5
Long - 41 stocks Short - 2 stoc	:ks			Healthcare Providers		14.5 3.5	14.5 3.5
1. Investment returns are calculated using the Fund's unit price and represent the combined income and				Misc Manufacturing		1.9	1.9
capital return for the specified period. They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax, and assume the reinvestment of distributions. The investment performance fee payable) are applied by the provided of the payable of th						1.3	1.3
investment returns shown are historical and no warranty can be given for future performance. You should be aware that historical performance is not a reliable indicator of future performance. Due to the Equity Funds							(1.7)
volatility of underlying assets of the Fund and other risk factors associated with investing, investment returns can be negative (particularly in the short-term).							
<ol><li>The investment returns depicted in inception relative to the MSCI All Control</li></ol>	Health Care Net Index i	Asset Management (Platinum) is Care Fund (the Fund). The Plating	um Trust Product Dis	closure Statement No.8 and S	Supplementary		
The investment returns are calculate They are net of fees and costs (exclude	-sell spread and any inve		Platinum's website, www.platinu	PDS (together PDS) provides details about the Fund. You can obtain a copy of the PDS from Platinum's website, www.platinum.com.au, or by contacting Investor Services on 1300 726 700			
payable), pre-tax and assume the reinvestment of distributions. It should be noted that Platinum does not invest by reference to the weightings of the Index. Underlying assets are chosen through Platinum's Invest@platinum.com.au.							
individual stock selection process and as a result holdings will vary considerably to the make-up of the Index. The Index is provided as a reference only.							
3. The "Long %" represents the exposure of physical h			particular investment needs, objectives and mancial circumstances. You should refer to the PDS when deciding to acquire, or continue to hold, units in the Fund. DISCLAIMER: The information presented in this Fact Sheet is not intended to be advice. It has not				
The "Currency %" represents the currency hedging.			DISCLAIMER: The information presented in this Fact Sheet is not intended to be advice. It has not been prepared taking into account any particular investor's or class of investor's investment objectives, financial situation or needs, and should not be used as the basis for making investment,				
4. Top Ten positions shows the Fund'		Long derivative exposures are	financial or other decisions. To t	objectives, infancial situation or needs, and should not be used as the basis for making investment, financial or other decisions. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. Platinum does not guarantee the repayment			
included, however, short derivative e	not.		of capital, payment of income or	the Fund's performa	nce.	e die repayment	
				Platinum is a member of the Plat	tinum Group of comp	anies.	